Requiring Humira Biosimilars Results in Huge Savings for Navitus Clients

Navitus achieved significant cost savings by removing Humira from its formularies and transitioning members to lower-cost biosimilars, resulting in more than $315 million in upfront savings and a 60% reduction in net cost per claim. Ryan Schmidt, Associate Director of Client Financial Support at Navitus, pointed to rising utilization trends while emphasizing biosimilar transitions as a key strategy for managing costs.